Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Indulgence
Premium
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
It is unlikely for Zydus Cadila to repeat US feat this year, say analysts
Analysts doubt if other Indian firms in the segment will do much better in the formulations business in the US
Cadila Healthcare surpasses Lupin to become 2nd most valuable pharma firm
Cadila Healthcare with m-cap of Rs 54,719 cr, stood ahead of Lupin, which have m-cap of Rs 52,217 cr
